Ryuichi Furuya

Prof. Dr. Ryuichi Furuya


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2005 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
RFRyuichi Furuya
Ryuichi Furuya
MOMari Odamaki
Mari Odamaki
HKHiromichi Kumagai
Hiromichi Kumagai
AHAkira Hishida
Akira Hishida
Objective. Leptin and adiponectin, well-recognized adipocytokines, are reported to contribute to the pathogenesis of atherosclerosis. The aim of this study was to elucidate the effects of icodextrin-based dialysis solution on adipocytokine metabolism.

16 June 2009 in Nephron Clinical Practice
Verified
Journal Article
Closed access
RFRyuichi Furuya
Ryuichi Furuya
HKHiromichi Kumagai
Hiromichi Kumagai
MOMari Odamaki
Mari Odamaki
MTMasaaki Takahashi
Masaaki Takahashi
AMAsumi Miyaki
Asumi Miyaki
AHAkira Hishida
Akira Hishida
Background: Residual renal function (RRF) affects the survival rate and the development of cardiovascular disease in peritoneal dialysis (PD) patients. We evaluated the impact of RRF on oxidative and carbonyl stress in PD patients. Methods: Plasma advanced oxidation protein products (AOPP) and pentosidine were measured in PD patients with a urine volume of ≥300 ml/day (group A, n = 17) and <300 ml/day (group B, n = 14). AOPP and pentosidine were reevaluated after 12 months of follow-up in group A. Results: Plasma levels of AOPP and pentosidine in group A were significantly lower than those in group B. Renal creatinine clearance was inversely correlated with AOPP (p < 0.05) and pentosidine (p < 0.01). After 12 months of follow-up, no significant change was observed in AOPP and pentosidine in groups who maintained a urine volume of ≥300 ml/day, but significantly increased in groups whose urine volume decreased to less than 300 ml/day. There were significant inverse relationships between the changes in renal creatinine clearance and AOPP (p < 0.01) and pentosidine (p < 0.05). Conclusion: Loss of RRF is associated with increased plasma AOPP and pentosidine, indicating that preservation of RRF has a beneficial effect in reducing the oxidative and carbonyl stress in PD patients.

20 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HFHirotaka Fukasawa
Hirotaka Fukasawa
RFRyuichi Furuya
Ryuichi Furuya
MKMai Kaneko
Mai Kaneko
DNDaisuke Nakagami
Daisuke Nakagami
YIYuri Ishino
Yuri Ishino
HYHideo Yasuda
Hideo Yasuda
The trace element zinc is essential for diverse physiological processes in humans. Zinc deficiency can impair growth, skin reproduction, immune function, maintenance of taste, glucose metabolism, and neurological function. Patients with chronic kidney disease (CKD) are susceptible to zinc deficiency, which is associated with erythropoiesis-stimulating agent (ESA) hypo-responsive anemia, nutritional problems, and cardiovascular diseases as well as non-specific symptoms such as dermatitis, prolonged wound healing, taste disturbance, appetite loss, or cognitive decline. Thus, zinc supplementation may be useful for the treatment of its deficiency, although it often causes copper deficiency, which is characterized by several severe disorders including cytopenia and myelopathy. In this review article, we mainly discuss the significant roles of zinc and the association between zinc deficiency and the pathogenesis of complications in patients with CKD.

9 December 2011 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
RFRyuichi Furuya
Ryuichi Furuya
HKHiromichi Kumagai
Hiromichi Kumagai
TMToshio Miyata
Toshio Miyata
HFHirotaka Fukasawa
Hirotaka Fukasawa
SIShinsuke Isobe
Shinsuke Isobe
AHAkira Hishida
Akira Hishida

1 September 2002 in Nephron
Verified
Journal Article
Closed access
PDF file
RFRyuichi Furuya
Ryuichi Furuya
HKHiromichi Kumagai
Hiromichi Kumagai
TSTadashi Sakao
Tadashi Sakao
YMYukitaka Maruyama
Yukitaka Maruyama
AHAkira Hishida
Akira Hishida
The present study was conducted to examine potassium lowering effect of exogenous mineralocorticoid (fludrocortisone acetate; FCA) administration to the patients with chronic renal failure undergoing hemodialysis. Fifteen patients on hemodialysis receiving FCA with its dosage gradually increased from 0 to 0.20 mg/day were observed for five successive 4-week periods. The serum potassium concentration was significantly decreased after FCA administration concomitant with the decrease of the salivary sodium to potassium ratio. Such decrease in serum potassium concentration was more significant in patients with <150 pg/ml of plasma aldosterone concentration (PAC) (low PAC group) than in those with ≧150 pg/ml of PAC (high PAC group). 0.05 mg of FCA was sufficient to lower serum potassium in low PAC group, while 0.15 mg of FCA was required for high PAC group. FCA administration did not affect serum sodium, chloride and bicarbonate concentrations. Body weight and blood pressure were not increased during the experimental periods. There were no significant changes in plasma level of glucose, insulin, epinephrine and norepinephrine. These results suggested that FCA could be effective to treat hyperkalemia without any adverse effects in patients undergoing hemodialysis.

1 December 2006 in Blood Purification
Verified
Journal Article
Closed access
RFRyuichi Furuya
Ryuichi Furuya
MOMari Odamaki
Mari Odamaki
HKHiromichi Kumagai
Hiromichi Kumagai
AHAkira Hishida
Akira Hishida
Background: Oxidative stress and adipocytokines are reported to contribute to the pathogenesis of atherosclerosis. Though the inhibition of the renin-angiotensin system is known to have beneficial effects on atherosclerosis, the exact mechanisms for this remain to be clarified. The aim of this study was to determine the effects of angiotensin II receptor blockers (ARB) on the oxidative stress and adipocytokines in peritoneal dialysis patients. Methods: Candesartan (8 mg/day), an ARB, was administered for 3 months to 8 nondiabetic patients on peritoneal dialysis. Plasma levels of advanced oxidation protein products (AOPP) and adiponectin were measured before and 3 months after candesartan administration, and 3 months after discontinuation. Results: Plasma AOPP level decreased from 377.5 to 305.6 µmol/l (p < 0.05) following the administration of candesartan and returned to 394.6 µmol/l (p < 0.05) by 3 months after the discontinuation of the drug. Plasma adiponectin level increased from 12.5 to 18.8 µg/ml (p < 0.05) by candesartan and decreased again to 14.4 µg/ml (p < 0.05) after discontinuation. There was a significant inverse relationship between changes in plasma level of adiponectin and AOPP (r = – 0.888, p < 0.01). Conclusion: Candesartan increases plasma adiponectin level in association with the reduction of oxidative stress in peritoneal dialysis patients. Candesartan may be useful in preventing atherosclerosis in peritoneal dialysis patients.